Pelvic inflammatory disease secondary prevention

Pelvic inflammatory disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Pelvic Inflammatory Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pelvic inflammatory disease secondary prevention On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pelvic inflammatory disease secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pelvic inflammatory disease secondary prevention

CDC on Pelvic inflammatory disease secondary prevention

Pelvic inflammatory disease secondary prevention in the news

Blogs on Pelvic inflammatory disease secondary prevention

to Hospitals Treating Pelvic inflammatory disease

Risk calculators and risk factors for Pelvic inflammatory disease secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Seyedmahdi Pahlavani, M.D. [2]

## Overview[edit | edit source]

Sexual partner evaluation and treatment are the mainstays of secondary prevention for PID.

## Secondary prevention[edit | edit source]

* Sexual partners of woman who diagnosed with PID in last 60 days of onset of her symptoms must be evaluated and treated for possible chlamydia or gonorrhea infection.
* Infected women should avoid sexual contact until they and their partners have completed the evaluation and treatment.[1]

## References[edit | edit source]

1. ↑ Workowski KA, Bolan GA (2015). "Sexually transmitted diseases treatment guidelines, 2015". MMWR Recomm Rep. 64 (RR-03): 1–137. PMID 26042815.

Template:WH Template:WS